Aaron J Scott, MD

-
Co-Program Leader, Clinical and Translational Oncology Program
Assistant Professor, Medicine
Biography
Dr. Aaron J Scott is an academic medical oncologist specializing in translational research and treatment of gastrointestinal malignancies. He is originally from Tucson, AZ, and earned a B.Sc. in Molecular and Cellular Biology at the University of Arizona. He attended medical school and earned his M.D. from the University of Arizona College of Medicine. He then completed his internal medicine residency and hematology/oncology fellowship training at the University of Colorado Hospital. During his time at UCH, he received specialized training in translational and clinical research in gastrointestinal malignancies. In the Fall of 2016, he joined Banner-University of Arizona Cancer Center as faculty with the GI Oncology group.
Cancer Focus
Dr. Scott's primary academic pursuit has been performing translational and clinical research in gastrointestinal malignancies. Dr. Scott's research and clinical interests center around discovery of novel treatment(s) for patients with GI cancers with an emphasis on colorectal cancer. Most recently, Dr. Scott has been investigating the MET kinase pathway as a target for anti-proliferation of colorectal cancer (CRC) explants in patient-derived tumor xenograft (PDX) models. The results of these experiments have led to the development of a Phase II investigator-initiated clinical trial. Dr. Scott carries active membership roles in SWOG and AGICC, and is the Principal Investigator of multiple clinical trials at Banner-UACC.
Selected Publications
Eckstrom, J., T. Bartels, I. Abraham, H. Patel, E. Elquza, A. J. Scott, S. Malangone, J. Hollings, and A. McBride, "A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.", Support Care Cancer, vol. 27, issue 3, pp. 873-878, 2019 Mar. PMID: 30090991
Scott, A. J., J. J. Arcaroli, S. M. Bagby, R. Yahn, K. M. Huber, N. J. Serkova, A. Nguyen, J. Kim, A. Thorburn, J. Vogel, et al., "Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.", Mol Cancer Ther, vol. 17, issue 10, pp. 2112-2122, 2018 Oct. PMCID: PMC6168336 PMID: 30026382
Scott, A. J., E-K. Song, S. Bagby, A. Purkey, M. McCarter, C. Gajdos, K. S. Quackenbush, B. Cross, T. M. Pitts, A. Choon Tan, et al., "Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.", PLoS One, vol. 12, issue 11, pp. e0187173, 2017. PMCID: PMC5665512 PMID: 29091939
Scott, A. J., W. A. Messersmith, and A. Jimeno, "Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.", Drugs Today (Barc), vol. 51, issue 4, pp. 223-9, 2015 Apr. PMID: 26020064
O'Neil, B. H., A. J. Scott, W. W. Ma, S. J. Cohen, L. Leichman, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, et al., "A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.", Ann Oncol, vol. 26, issue 9, pp. 1923-9, 2015 09. PMCID: PMC4551155 PMID: 26091808